Swedish Orphan Biovitrum (Buy, TP: SEK330.00) - Truly transformative
The recently announced acquisition is set to be transformative for Sobi. Synagis should generate a steady revenue stream with a healthy EBITA margin, boosting earnings significantly near-term. The follow-up asset MEDI8897 holds potential that reaches far beyond the addressable market for Synagis. However, we would like to hear the outcome of the end-of-phase-II meeting with the FDA late in 2019/early in 2020 before we draw any conclusions on the market potential for MEDI8897. We reiterate our BUY but have cut our target price to SEK330 (340).Swedish Orphan Biovitrum AB is a healthcare company focused on rare diseases. Co. develops, manufactures and commercializes treatments with a particular focus on four therapeutic areas: Inflammation, Genetics & Metabolism, Haemophilia and Neonatology. Co. also markets a portfolio of rare disease products for partner companies. Co.'s pipeline programmes include research and development focused on recombinant protein drugs in late preclinical and clinical phase for indications.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.